Vancouver, B.C. – March 23, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FRA: 6UF) (“NeonMind”), provides an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder and as an aid to weight loss and its maintenance. NeonMind President and CEO Rob Tessarolo Reports: “It is a very exciting time to be in the psychedelic industry, which is undergoing rapid expansion. There is a continuous flow of new companies entering the ...
[ more ]
